CLINICAL USE


Benzodiazepine:Insomnia (short-term use) Pre-med anxiolytic prior to minor procedures

DOSE IN NORMAL RENAL FUNCTION

10–40 mg at night Premedication: 20–40 mg, 60 minutes prior to procedure

PHARMACOKINETICS

  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :300.7
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :96
  • %Excreted unchanged in urine &nbsp &nbsp : <2
  • Volume of distribution (L/kg) &nbsp &nbsp &nbsp :1.3–1.5
  • half-life – normal/ESRD (hrs)&nbsp &nbsp &nbsp :7–11/Unchanged

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function. Start with small doses
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function. Start with small doses

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Unlikely to be dialysed. Dose as in GFR <10 mL/min

  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Not dialysed. Dose as in GFR <10 mL/min
  • HDF/high flux &nbsp :Unknown dialysability. Dose as in GFR <10 mL/min
  • CAV/VVHD &nbsp &nbsp &nbsp:Not dialysed. Dose as in GFR 10 to 20 mL/min

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugs
  • Antibacterials: metabolism possibly increased by rifampicin
  • Antipsychotics: increased sedative effects
  • Antivirals: concentration possibly increased by ritonavirDisulfiram: metabolism of temazepam inhibited (increased toxicity)Sodium oxybate: enhanced effects of sodium oxybate – avoid

    ADMINISTRATION

    Reconstition

    Route

    Oral

    Rate of Administration

    Comments

    OTHER INFORMATION

    Increased CNS sensitivity in renal impairmentLong-term use may lead to dependence and withdrawal symptoms in certain patients80% of metabolites excreted in the urine